Solid Lipid Nanoparticles: Fundamentals, Design and Applications
Chapter 14 - Future Trends and Emerging Applications of Solid Lipid Nanoparticles
Anita Ashok Bandgar, Samrat Yashwant Ghatge, Akshay Ishwarchand Pawar
Abstract:
Solid lipid nanoparticles (SLNs) represent a transformative advancement in drug delivery systems, offering superior biocompatibility, stability, and controlled release compared to conventional methods. This chapter explores emerging trends in SLN technology, focusing on innovations that enhance precision, efficacy, and sustainability. Key developments include surface modifications (e.g., antibody conjugation, PEGylation)for targeted delivery, hybrid nanocarrier systems combining SLNs with liposomes or polymers for multifunctional therapy, and stimuli-responsive SLNs that release drugs in response to pH, temperature, or enzymes. SLNs are also revolutionizing gene and RNA delivery, building on mRNA vaccine success to enable CRISPR-based therapies and personalized medicine. The chapter highlights green formulation approaches, such as solvent-free production and natural lipids, which reduce environmental impact while improving therapeutic performance. Scalability challenges are addressed through advanced manufacturing techniques like high-pressure homogenization, paving the way for clinical and commercial translation. Applications span targeted cancer therapy (reducing systemic toxicity), CNS drug delivery (overcoming the blood-brain barrier), dermatology (enhanced skin penetration), and antimicrobial delivery (combating resistance). The integration of AI-driven design further enables personalized SLNs tailored to individual genetic and disease profiles. Collectively, these advancements position SLNs as a versatile platform for next-generation medicine, offering safer, more effective treatments across diverse therapeutic areas while aligning with global sustainability goals. Future directions include smart nanoparticles, closed-loop systems, and scalable production for widespread clinical adoption.
Keywords: AI-driven design, biocompatibility, blood-brain barrier, CRISPR, drug delivery, gene therapy, green formulation, hybrid nanocarriers, mRNA vaccines, nanotechnology, personalized medicine, scalability, solid lipid nanoparticles (SLNs), stimuli-responsive, sustainability, targeted therapy.
References:
[1] Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177
[2] Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951.
[3] Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci. 2018;13(4):288-303.
[4] Patel S, Shukla A, Sapra B. Hybrid nanoparticles for combination therapy of cancer. J Control Release. 2019;311-312:253-270.
[5] Ramasamy T, Ruttala HB, Chitrapriya N, Poudel BK, Choi H-G, Yong CS, et al. Engineering of stimuli-responsive solid lipid nanoparticles for controlled release and targeting. Biomater Sci. 2019;7(6):2202–2217.
[6] Sahana B, Mittal G, Bhardwaj V, Kumar M, Reddy LH, Ravi Kumar MNV. Programmable lipid–polymer hybrid nanoparticles for stimuli-sensitive delivery of anti-cancer agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6(5):486–501.
[7] Wang Y, Su HH, Yang Y, Hu Y, Zhang L, Blancafort P, et al. Gene delivery systems: an updated review. Nat Rev Drug Discov. 2013;12(4):329–344.
[8] Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Mol Ther. 2019;27(4):757–772.
[9] Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28-51.
[10] Gao X, Kim KS, Liu D. Nonviral gene delivery: what we know and what is next. Theranostics. 2014;4(4):353–366.
[11] Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3):165–196.
[12] Sharma A, Ahmad H, Bhat SA, Iqbal D, Mohd S, Pandey A. Green nanotechnology: applications and potential in drug delivery. J Clean Prod. 2020;258:122439.
[13] Jenning V, Schäfer-Korting M, Gohla SH. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. Int J Pharm. 2000;214(1-2):17–19.
[14] Beloqui A, Solinís MA, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Int J Nanomedicine. 2012;7:750891.
[15] Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Nat Rev Drug Discov. 2004;3(8):711–716.
[16] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760.
[17] Sanchez-Lopez E, Ettcheto M, Egea MA, Espina M, Cano A, Camins A, et al. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization. Front Aging Neurosci. 2019;11:373.
[18] Pandey A, Dhabarde D, Gupta S. Nanoparticle-based intranasal delivery in central nervous system disorders. Pharmaceutics. 2019;11(5):269.
[19] Lainšček D, Tolar T, Pohar J, Štokelj M, Hafner-Bratkovič I, Jerala R. Delivery of mRNA therapeutics for cancer treatment. Nucleic Acid Ther. 2020;30(6):333–345.
[20] Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–1094.
[21] Rahman A, Harwansh RK, Mirza MA, Hussain S, Hussain A. Oral delivery of herbal bioactives using nanotechnology. J Drug Deliv Sci Technol. 2020;55:101876.
[22] Gaspar DP, Faria V, Gonçalves LM, Taveira SF, Veiga FJ. Solid lipid nanoparticles as a delivery system for amphotericin B. J Control Release. 2011;150(1):75–77.
[23] Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8(3):184–187.